News

Biogen R&D chief Williams leaves for biotech startup

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Aerie plots an R&D expansion after an FDA rebound for its lead drug

Aerie Pharmaceuticals, regaining momentum after a costly clinical setback, is planning to expand its R&D operation in North Carolina, pressing forward with a treatment for glaucoma.

Singapore's big biotech push yields its first clinical contender

Singapore, a nation working to raise its profile in the biopharma world, has kicked off the first-ever clinical trial of a locally invented drug, working with Duke University on a novel cancer treatment it hopes will spur more R&D.

Lilly and Biogen prep make-or-break Alzheimer's data amid an amyloid renaissance

Biogen and Eli Lilly, two drugmakers making big bets in Alzheimer's disease, are set to present clinical data on a pair of much-scrutinized projects with potential to change the industry's approach to the field.

Pint-sized biotechs join the IPO queue as Wall Street cash pours in

Biotech's protracted IPO hot streak is attracting drug developers of all sizes to the Wall Street trough, including a pair of companies eyeing micro-offerings in hopes of funding their lead programs.

UPDATED: Torrid pace of VC investing in H1 sets a new biotech record

The venture money machine backing the biotech industry in the U.S. was operating in overdrive during the second quarter, generating a record amount of investing in new drug development as IPOs continue their romp in the third year of a wide-open market.

DBV files to raise $245M; Imperial Innovations lands £50M loan; Pfizer backs Autifony round

In this week's EuroBiotech Report, Imperial Innovations snagged a £50 million ($78 million) loan from the European Investment Bank and chipped in to an £8 million Series A extension at Autifony. Securing the loan facility brings the amount Imperial Innovations has tapped EIB for since July 2013 up to £80 million, a sum that is contributing to an acceleration of its investment plans. And more.

AMRI shells out $174M for a Spanish drugmaker

Contract drug developer AMRI bought Spain's Gadea Pharmaceutical for $174 million, picking up a company focused on the manufacture of active ingredients and finished treatments.

Five Prime bets up to $452.5M on Inhibrx's cancer antibodies

Five Prime Therapeutics is buying to Inhibrx's early-stage cancer R&D, signing a deal worth up to $452.5 million to get its hands on an immuno-oncology project.

Playing defense, Baxalta makes its case for a new hemophilia drug

Fresh off of completing its spinout from Baxter, Baxalta has unveiled the positive data it's using to back an approval for BAX 855, a long-acting factor VIII-replacement therapy that's designed to do a better job at producing blood clots for hemophilia A patients.

Blazing biotech IPO market continues to deliver a fortune for startups

The go-go market for biotech IPOs is steaming ahead, pushing two more developers onto Nasdaq with a combined $239 million payoff at above-range prices. And biotech billionaire Patrick Soon-Shiong set a price range on his upcoming IPO for NantKwest at $20 to $23 a share, looking to raise around $160 million--or more--based on a company valuation of $2.2 billion.

FierceBiotech Radio on Celgene's $7.2B splash, Sanofi's shakeup, and GSK's big, bad wolf

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including Celgene's planned acquisition of Receptos, Sanofi's latest corporate restructuring and an alarming new ad from GlaxoSmithKline.

Protagonist Therapeutics lands $40M round for an oral peptide IBD drug

Overcoming the challenges of creating an oral peptide drug aimed at irritable bowel disease is the business model behind Protagonist Therapeutics, a Milpitas, CA-based biotech that is celebrating a new, $40 million round designed to pay for the early-stage clinical work needed to prove its drug candidate can work in humans.

DBV files to raise $245M to fuel race for peanut allergy market

DBV Technologies has filed for a $245 million (€224 million) share offering. Almost 40% of the mighty sum is earmarked for development of treatments for milk and peanut allergies, which the French biotech is trying to hustle to market ahead of its rivals' competitors.

UPDATED: T-cell pioneer Immunocore scores a record-breaking $320M round

In another demonstration of the big bets being made on reengineering T cells to attack cancer, Oxford, U.K.-based Immunocore has come up with a monster $320 million venture round designed to push the pipeline well past positive early stage data for its lead therapy.

Pfizer, SV give GSK spinout money to expand into schizophrenia research

Autifony Therapeutics has returned to its investors for £8 million ($12 million) to fund a broadening of its R&D ambitions. The company, which spun out of GlaxoSmithKline with an age-related hearing loss program in 2011, is now going after schizophrenia.

AC Immune snags milestone as Genentech picks Alzheimer's asset to advance to clinic

AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.

U.K. puts Cambridge at the heart of £50M precision medicine program

The United Kingdom has put Cambridge at the heart of its £50 million ($78 million) push into precision medicines. Cambridge is to host the headquarters of the precision medicine network, from which a team will coordinate regional centers to support the advance of targeted therapies through the clinic and into real-world use.

EU bank funnels £50M into Imperial Innovations as investment plan accelerates

Imperial Innovations has returned to the European Investment Bank for cash, signing off on a £50 million ($78 million) loan just two years after it tapped the same source for £30 million. The need to double-dip in the EIB funding font arose after Imperial Innovations stepped up its rate of investment.

Apogenix inks cancer drug development deal for China

Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize its lead immuno-oncology drug candidate APG101 in ChinaMacao, and Hong Kong.